Close Menu

NEW YORK – Patients with advanced urothelial cancer characterized by HRAS mutations saw their tumors shrink after treatment with Kura Oncology's lead investigational drug tipifarnib in a Phase II proof-of-concept study.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.